Isatuximab

Generic Name
Isatuximab
Brand Names
Sarclisa
Drug Type
Biotech
Chemical Formula
-
CAS Number
1461640-62-9
Unique Ingredient Identifier
R30772KCU0
Background

Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on th...

Indication

Isatuximab is indicated in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. It is also indicated in combination carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple ...

Associated Conditions
Multiple Myeloma (MM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Associated Therapies
-
Clinical Trials
Related News

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Phase 2
Recruiting
Conditions
Monoclonal Gammopathy
Interventions
Drug: Isatuximab
First Posted Date
2020-11-04
Last Posted Date
2024-03-06
Lead Sponsor
Columbia University
Target Recruit Count
27
Registration Number
NCT04614558
Locations
🇺🇸

Massachusetts General Hospital, Renal Associates Clinic, Boston, Massachusetts, United States

🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

Phase 2
Recruiting
Conditions
Multiple Myeloma
Interventions
Drug: CellProtect
Drug: Isatuximab
First Posted Date
2020-09-22
Last Posted Date
2023-10-11
Lead Sponsor
Karolinska Institutet
Target Recruit Count
62
Registration Number
NCT04558931
Locations
🇸🇪

Karolinska University Hospital, Huddinge, Stockholm, Sweden

KRDI in Transplant-Eligible MM

First Posted Date
2020-06-12
Last Posted Date
2024-12-06
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
50
Registration Number
NCT04430894
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

First Posted Date
2020-02-27
Last Posted Date
2023-01-10
Lead Sponsor
Poitiers University Hospital
Target Recruit Count
82
Registration Number
NCT04287855
Locations
🇫🇷

CHU Poitiers, Poitiers, France

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients

First Posted Date
2020-01-27
Last Posted Date
2024-01-09
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
41
Registration Number
NCT04240054
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

First Posted Date
2019-10-15
Last Posted Date
2024-02-26
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
464
Registration Number
NCT04126200
Locations
🇸🇪

GSK Investigational Site, Stockholm, Sweden

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

First Posted Date
2019-06-18
Last Posted Date
2024-11-28
Lead Sponsor
Celgene
Target Recruit Count
424
Registration Number
NCT03989414
Locations
🇺🇸

Local Institution - 110, Winston-Salem, North Carolina, United States

🇨🇿

Local Institution - 802, Brno, Czechia

🇨🇿

Local Institution - 801, Ostrava-Poruba, Czechia

and more 46 locations

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

First Posted Date
2019-03-04
Last Posted Date
2024-05-16
Lead Sponsor
Sanofi
Target Recruit Count
67
Registration Number
NCT03860844
Locations
🇺🇸

Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States

🇲🇽

Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico

🇧🇷

Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil

and more 38 locations

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

First Posted Date
2018-08-06
Last Posted Date
2023-05-12
Lead Sponsor
University of Heidelberg Medical Center
Target Recruit Count
662
Registration Number
NCT03617731
Locations
🇩🇪

Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin, Bad Saarow, Germany

🇩🇪

Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, Germany

🇩🇪

Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie, Darmstadt, Germany

and more 70 locations

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

First Posted Date
2018-06-13
Last Posted Date
2023-11-07
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
96
Registration Number
NCT03555149
Locations
🇫🇷

Centre Leon Berard, Lyon, France

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 12 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy